Welcome to LookChem.com Sign In|Join Free

CAS

  • or
4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95% and 4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER are organic compounds that belong to the class of boronic acid pinacol esters. They are commonly used in chemical research and synthesis, with the former being available in a 95% pure form. These compounds are significant in the field of organic chemistry, particularly for the development of new pharmaceuticals and agrochemicals. Their unique reactivity and versatility make them valuable in the preparation of complex molecules and materials.

874290-99-0

Post Buying Request

874290-99-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95%4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER

    Cas No: 874290-99-0

  • USD $ 3.0-3.0 / Kilogram

  • 1 Kilogram

  • 1-100 Metric Ton/Month

  • Dayang Chem (Hangzhou) Co.,Ltd.
  • Contact Supplier
  • 1-METHYL-3-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)UREA

    Cas No: 874290-99-0

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 874290-99-0 C14H21BN2O3 4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95%4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER

    Cas No: 874290-99-0

  • No Data

  • 1 Metric Ton

  • Metric Ton/Day

  • HENAN NEW BLUE CHEMICAL CO.,LTD
  • Contact Supplier
  • 4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95%4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER

    Cas No: 874290-99-0

  • USD $ 10.0-10.0 / Milligram

  • 1 Milligram

  • 100000000 Kilogram/Month

  • weifang yangxu group co.,ltd
  • Contact Supplier

874290-99-0 Usage

Uses

Used in Pharmaceutical Industry:
4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95% and 4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER are used as key components in the development of new pharmaceuticals. Their unique reactivity and versatility allow for the synthesis of complex molecules with potential therapeutic applications.
Used in Agrochemical Industry:
These boronic acid pinacol esters are also utilized in the development of new agrochemicals, contributing to the creation of innovative products for agricultural applications.
Used in Chemical Research:
4-[(METHYLCARBAMOYL)AMINO]BENZENEBORONIC ACID, PINACOL ESTER 95% and 4-(3-METHYLUREIDO)BENZENEBORONIC ACID, PINACOL ESTER serve as important compounds in chemical research, enabling the exploration of new synthetic pathways and the discovery of novel chemical reactions.
Used in Material Science:
Due to their unique reactivity, these boronic acid pinacol esters are employed in the preparation of various complex materials, contributing to advancements in material science and the development of new materials with specific properties.

Check Digit Verification of cas no

The CAS Registry Mumber 874290-99-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,2,9 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 874290-99:
(8*8)+(7*7)+(6*4)+(5*2)+(4*9)+(3*0)+(2*9)+(1*9)=210
210 % 10 = 0
So 874290-99-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H21BN2O3/c1-13(2)14(3,4)20-15(19-13)10-6-8-11(9-7-10)17-12(18)16-5/h6-9H,1-5H3,(H2,16,17,18)

874290-99-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H53000)  4-(3-Methylureido)benzeneboronic acid pinacol ester, 95%   

  • 874290-99-0

  • 250mg

  • 882.0CNY

  • Detail
  • Alfa Aesar

  • (H53000)  4-(3-Methylureido)benzeneboronic acid pinacol ester, 95%   

  • 874290-99-0

  • 1g

  • 2822.0CNY

  • Detail

874290-99-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-Methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea

1.2 Other means of identification

Product number -
Other names 1-methyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:874290-99-0 SDS

874290-99-0Downstream Products

874290-99-0Relevant articles and documents

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

-

Paragraph 0401; 0898-0900, (2020/01/08)

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS

-

Paragraph 1776-1777, (2017/05/19)

Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Discovery of AZD3147: A potent, selective dual inhibitor of mTORC1 and mTORC2

Pike, Kurt G.,Morris, Jeff,Ruston, Linette,Pass, Sarah L.,Greenwood, Ryan,Williams, Emma J.,Demeritt, Julie,Culshaw, Janet D.,Gill, Kristy,Pass, Martin,Finlay, M. Raymond V.,Good, Catherine J.,Roberts, Craig A.,Currie, Gordon S.,Blades, Kevin,Eden, Jonathan M.,Pearson, Stuart E.

, p. 2326 - 2349 (2015/03/30)

High throughput screening followed by a lead generation campaign uncovered a novel series of urea containing morpholinopyrimidine compounds which act as potent and selective dual inhibitors of mTORC1 and mTORC2. We describe the continued compound optimization campaign for this series, in particular focused on identifying compounds with improved cellular potency, improved aqueous solubility, and good stability in human hepatocyte incubations. Knowledge from empirical SAR investigations was combined with an understanding of the molecular interactions in the crystal lattice to improve both cellular potency and solubility, and the composite parameters of LLE and pIC50-pSolubility were used to assess compound quality and progress. Predictive models were employed to efficiently mine the attractive chemical space identified resulting in the discovery of 42 (AZD3147), an extremely potent and selective dual inhibitor of mTORC1 and mTORC2 with physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

-

, (2014/10/29)

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

-

Page/Page column 48, (2010/11/04)

A compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

5, 6, 7, 8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR, PI3, AND HSMG-1 KINASE INHIBITORS, AND THEIR SYNTHESES

-

Page/Page column 43, (2010/11/04)

A compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS

-

Page/Page column 26, (2009/06/27)

A pyrrolo[3,2-d]pyrimidine compound, such as a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the

ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines

Zask, Arie,Verheijen, Jeroen C.,Curran, Kevin,Kaplan, Joshua,Richard, David J.,Nowak, Pawel,Malwitz, David J.,Brooijmans, Natasja,Bard, Joel,Svenson, Kristine,Lucas, Judy,Toral-Barza, Lourdes,Zhang, Wei-Guo,Hollander, Irwin,Gibbons, James J.,Abraham, Robert T.,Ayral-Kaloustian, Semiramis,Mansour, Tarek S.,Yu, Ker

supporting information; experimental part, p. 5013 - 5016 (2010/03/04)

The mammalian target of rapamycin (mTOR), a central regulator of growth, survival, and metabolism, is a validated target for cancer therapy. Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex. ATP-competitive, global inhibitors of mTOR that have the potential for enhanced anticancer efficacy are described. Structural features leading to potency and selectivity were identified and refined leading to compounds with in vivo efficacy in tumor xenograft models.

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituent

Verheijen, Jeroen C.,Richard, David J.,Curran, Kevin,Kaplan, Joshua,Lefever, Mark,Nowak, Pawel,Malwitz, David J.,Brooijmans, Natasja,Toral-Barza, Lourdes,Zhang, Wei-Guo,Lucas, Judy,Hollander, Irwin,Ayral-Kaloustian, Semiramis,Mansour, Tarek S.,Yu, Ker,Zask, Arie

experimental part, p. 8010 - 8024 (2010/07/04)

Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d] pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase α (PI3K-α), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC50 against mTOR and greater than 1000-fold selectivity over PI3K-α. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC50501 nM). 2009 American Chemical Society.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 874290-99-0